Yongin-si, South Korea

Woo Young Kwak

USPTO Granted Patents = 8 


 

Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Kyonggi-do, KR (2009)
  • Yongin-si, KR (2011 - 2016)
  • Gyeonggi-do, KR (2017)
  • Seoul, KR (1998 - 2021)

Company Filing History:


Years Active: 1998-2021

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Inventor Woo Young Kwak: Innovations in Dipeptidyl Peptidase-IV Inhibitors

Introduction: Woo Young Kwak is a notable inventor based in Yongin-si, South Korea, recognized for his contributions in the field of pharmaceuticals. With a total of four patents, his work primarily focuses on methods for preparing and manufacturing dipeptidyl peptidase-IV inhibitors, which play a critical role in diabetes management.

Latest Patents: One of his latest patents, titled "Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate," describes an improved approach to producing these inhibitors. This method utilizes low-cost reagents to reduce preparation costs and enhance yield, making it suitable for mass production. Another significant patent is "Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate," which similarly emphasizes cost reduction through the use of affordable reagents while also ensuring a boost in production yield and adaptability for large-scale manufacturing.

Career Highlights: Woo Young Kwak has had a distinguished career, having worked at reputable companies such as Dong-A Pharmaceutical Co., Ltd. and Dong-A Pharm. Co., Ltd. His dedication to advancing pharmaceutical technologies is evident through his innovative approaches to drug production.

Collaborations: Throughout his career, Woo Young Kwak has collaborated with esteemed colleagues, including Heung Jae Kim and Jong Pil Min. These partnerships exemplify the collaborative spirit in research and development, contributing to the efficacy of his inventions.

Conclusion: Woo Young Kwak remains a significant figure in the field of pharmaceutical innovations. His patented methods for producing dipeptidyl peptidase-IV inhibitors not only advance scientific understanding but also offer practical solutions for mass production, thereby enhancing the availability of vital medications in diabetes treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…